These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26468083)

  • 1. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.
    Simone V; Ciavarella S; Brunetti O; Savonarola A; Cives M; Tucci M; Opinto G; Maiorano E; Silvestris F
    BMC Cancer; 2015 Oct; 15():692. PubMed ID: 26468083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteoclast Factors of Breast Cancer Cells.
    Vashum Y; Kottaiswamy A; Bupesh G; Singh RP; Kalaiselvan P; Thiagarajan K; Samuel S
    Curr Mol Pharmacol; 2021; 14(6):1134-1145. PubMed ID: 33573566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.
    Mercatali L; Spadazzi C; Miserocchi G; Liverani C; De Vita A; Bongiovanni A; Recine F; Amadori D; Ibrahim T
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27809291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
    Hadji P; Coleman R; Gnant M
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
    Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
    Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
    Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
    Hussein O; Tiedemann K; Komarova SV
    Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling.
    Hsieh CJ; Kuo PL; Hou MF; Hung JY; Chang FR; Hsu YC; Huang YF; Tsai EM; Hsu YL
    Int J Oncol; 2015 Feb; 46(2):555-62. PubMed ID: 25421824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.
    Browne AJ; Kubasch ML; Göbel A; Hadji P; Chen D; Rauner M; Stölzel F; Hofbauer LC; Rachner TD
    Breast Cancer Res; 2017 Aug; 19(1):92. PubMed ID: 28793923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
    Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
    Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
    Gordon AH; O'Keefe RJ; Schwarz EM; Rosier RN; Puzas JE
    Cancer Res; 2005 Apr; 65(8):3209-17. PubMed ID: 15833852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gentian violet inhibits MDA-MB-231 human breast cancer cell proliferation, and reverses the stimulation of osteoclastogenesis and suppression of osteoblast activity induced by cancer cells.
    Yamaguchi M; Vikulina T; Weitzmann MN
    Oncol Rep; 2015 Oct; 34(4):2156-62. PubMed ID: 26260090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
    Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryoprotective isoliquiritigenin-zein phosphatidylcholine nanoparticles inhibits breast cancer-bone metastasis by targeting JAK-STAT signaling pathways.
    Ganesan K; Xu C; Xie C; Sui Y; Zheng C; Gao F; Chen J
    Chem Biol Interact; 2024 Jun; 396():111037. PubMed ID: 38719172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
    Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
    J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
    Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
    Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
    Pivetta E; Scapolan M; Pecolo M; Wassermann B; Abu-Rumeileh I; Balestreri L; Borsatti E; Tripodo C; Colombatti A; Spessotto P
    Breast Cancer Res; 2011 Oct; 13(5):R105. PubMed ID: 22032644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.